Clinical trials: Hair Diseases
Alopecia Areata (AA)
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
- Trial name
- NCT06060977
- Testing
- IMG-007
- Where
- 17 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Inmagene LLC
Alopecia
The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
A study to evaluate the pharmacokinetics, pharmacodynamics, and safety of CKD-843 A in male subjects.
- Trial name
- NCT05587699
- Testing
- CKD-843 A 45mg(Multiple dose), CKD-843 A 45mg, CKD-843 A 55mg(Multiple dose)
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hair Thinning
Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair
The objective of this study is to assess the effectiveness and safety of a novel dietary supplement containing botanical ingredients for hair thinning in men over the course of six months of continuous daily usage.
- Trial name
- NCT05339958
- Testing
- Nutrafol® Men Hair Growth Nutraceutical
- Where
- 2 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Nutraceutical Wellness Inc.
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP1 (NCT05910450)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 24 sites in United States, Georgia
- Volunteers
- 703 people
- Sponsor
- Cassiopea SpA
Alopecia Areata
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks.
- Trial name
- NCT02974868
- Testing
- PF-06651600, PF-06700841
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 142 people
- Sponsor
- Pfizer
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Sensorineural Hearing Loss, Tinnitus
Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
The HEAR-RESTORE study is an exploratory clinical research program designed to evaluate new diagnostic and regenerative approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss.
- Conditions
- Sensorineural Hearing Loss, Tinnitus, Acoustic Trauma, Inner Ear Injury
- Trial name
- HEAR-RESTORE (NCT07472023)
- Testing
- Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy, Stem Cell Regenerative Therapy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
- Trial name
- NCT02279823
- Testing
- CB-03-01 solution, Minoxidil Solution 5%
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Intrepid Therapeutics, Inc.
Alopecia
Fractional Non-ablative Laser for the Treatment of Hair Loss
This is a single center, prospective, open label clinical trial with before-after study design. The study is designed to evaluate the feasibility of hair growth in female and male pattern hair loss (androgenic alopecia, telogen…
- Trial name
- NCT04953416
- Testing
- 1565nm non ablative fractional laser
- Where
- Ukraine
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Lumenis Be Ltd.
Allergy
Phase 2 Study in Adults Sensitized to Cat
The purpose of this study is to identify an effective dose of allergen-specific immunotherapy for cat hair (Felis domesticus) administered by the oral/sublingual route.
- Trial name
- NCT00689299
- Testing
- Standardized Allergenic Extract, Cat Hair
- Where
- 3 sites in United States
- Volunteers
- 167 people
- Sponsor
- Antigen Laboratories, Inc.
Androgenetic Alopecia, Female Pattern Baldness
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss).
- Trial name
- NCT05888922
- Testing
- Minoxidil Tablets, Minoxidil Topical, Vehicle solution
- Where
- 27 sites in Germany, Italy and 2 more
- Volunteers
- 520 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia
Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss.
- Trial name
- NCT06590779
- Testing
- Aminexil® active+ lotion, Finasteride 1mg
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.
- Trial name
- BRAVE-AA1 (NCT03570749)
- Testing
- Baricitinib
- Where
- 75 sites in United States, Japan and 3 more
- Volunteers
- 784 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
Clinical Trial to Evaluate Effectiveness of a Probiotic Preparation Administered to Patients With Alopecia Areata
This study is part of a broader project that proposes the characterization of what we call the "Entire-Systemic Axis". It aims to study whether the bacteria present in the human skin microbiota and in the human intestinal…
- Trial name
- NCT05599607
- Testing
- Probiotic mixture
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Bioithas SL
Acne Vulgaris, Folliculitis
Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, and Folliculitis
The Research Question of the present study is the following: in a population of men and women affected by acne vulgaris, and folliculitis, will Ialuxid® Gel (hydrogen peroxide, hyaluronic acid and glycine) improve the course of…
- Trial name
- NCT05345093
- Testing
- Ialuxid gel
- Where
- Romania
- Volunteers
- 66 people
- Sponsor
- BMG Pharma
Alopecia, Androgenetic
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- NCT05244980
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Thin Hair, Hair Loss
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth by applying a serum daily on the scalp of men and women with thinning hair. The main aims of this trial are: 1.
- Conditions
- Thin Hair, Hair Loss, Alopecia, Thinning Hair
- Trial name
- NCT07228156
- Testing
- Xtresse Serum
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Trichotillomania
Technology Assisted Treatment of Trichotillomania: Open Trial
This open-label feasibility trial evaluates the use of the Keen2 awareness bracelet for adults with trichotillomania (hair-pulling disorder). Participants will use the bracelet for eight weeks.
- Trial name
- NCT07224126
- Testing
- Keen2 Predictive Awareness Bracelet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HabitAware Inc.